Compare WTBA & ALDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WTBA | ALDX |
|---|---|---|
| Founded | 1893 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 375.9M | 317.7M |
| IPO Year | 2002 | 2014 |
| Metric | WTBA | ALDX |
|---|---|---|
| Price | $23.80 | $1.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $24.00 | $5.50 |
| AVG Volume (30 Days) | 28.1K | ★ 5.3M |
| Earning Date | 04-23-2026 | 05-13-2026 |
| Dividend Yield | ★ 4.19% | N/A |
| EPS Growth | 35.21 | ★ 40.43 |
| EPS | ★ 1.92 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.69 | N/A |
| Revenue Next Year | $9.18 | $9.72 |
| P/E Ratio | $12.44 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $17.33 | $1.07 |
| 52 Week High | $26.60 | $6.54 |
| Indicator | WTBA | ALDX |
|---|---|---|
| Relative Strength Index (RSI) | 47.60 | 29.14 |
| Support Level | $23.57 | $1.07 |
| Resistance Level | $24.16 | $5.75 |
| Average True Range (ATR) | 0.72 | 0.38 |
| MACD | 0.05 | -0.16 |
| Stochastic Oscillator | 67.10 | 15.89 |
West Bancorp Inc is a United States-based company that offers a full range of deposit services, including checking, savings and money market accounts and time certificates of deposit. West Bank also offers online banking, mobile banking, and treasury management services, which help to meet the banking needs of its customers. Treasury management services offered to business customers include cash management, client-generated automated clearing house transactions, remote deposit, and fraud protection services. Also offered are merchant credit card processing and corporate credit cards. The bank operates only in the United States of America region.
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases. The company's product candidate, Reproxalap, is a treatment in late-stage development for dry eye disease and allergic conjunctivitis. In addition, it also has additional product candidates in development for proliferative vitreoretinopathy, primary vitreoretinal lymphoma and other retinal diseases, autoimmune disease, and cancer. Company products includes ADX248, ADX743, ADX631, ADX246, ADX629, ADX2191.